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Molecular Construction of “Soluble RTK” Proteins
A major class of proteins associated with cancer are receptor tyrosine kinases 
(RTKs), which are involved in molecular signaling related to cell growth and 
proliferation. RTKs are composed of an integral membrane protein domain that is 
embedded in the membrane and a cytosolic (soluble) kinase domain. The cytosolic 
kinase domain becomes activated upon dimerization mediated by the integral 
membrane domain upon binding to biosignaling molecules (hormones).  Drug 
therapies targeting the RTKs have largely focused on designing molecules that 
interact with the integral membrane domain, which binds to the signaling 
molecules, but have largely overlooked the kinase domain. Developing drugs to 
the kinase domain is difficult since the RTK protein is insoluble due to the 
presence of the integral membrane portion and removal of the protein from the 
membrane for studying drug binding can lead to denaturation and inactivation of 
the protein. The research presented here looks at developing artificial kinase 
receptors by replacing the integral membrane domain with soluble coiled coil 
forming peptides that can mimic the normal function of the integral membrane 
domain, i.e. dimerization, but produce a soluble artificial kinase receptor fusion 
protein mimic that can be used in drug screening assays to discover new RTK 
kinase domain inhibitors.
-Developing drugs targeting the kinase domain (KD) is difficult due to the presence of 
the ligand/transmembrane domains and insoluble nature of the transmembrane domain.
-Developing a soluble protein that contains the KD (EGFR in figure 3), but has a soluble 
domain that mediates dimerization would be useful for screening KD drug candidates.
-E. coli expression of P1-EGFR produces insoluble protein that cannot be refolded into an 
active conformation.
-Expression of P1-EGFR in insect cells has shown active soluble protein due to self 
dimerization of the P1 that was not reported in the literature.
-On-going efforts are focused on insect cell expression using an alternate set of coiled coil 
peptides that have been used in protein dimerization.
Figure 2. Asymmetric dimer formation and activation of kinase domains (adapted from reference 2). 
Preliminary Protein Expression and Purification of P1-EGFR
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Figure 6. pET28b vector indicating NcoI, BamHI , and XhoI 
cloning sites for gene insertion.







-RTKs are insoluble membrane bound proteins due to the integral transmembrane 
domain.
-Dimerization is essential from activation of the kinase domains upon binding of a ligand.
-Drugs for RTKs largely target the ligand binding/transmembrane domain.
-Coiled coils are structural motifs found in proteins 
whereby 2 or more alpha-helices wrap around one 
another.
-Coiled coils are characterized by a heptad repeat of 
amino acids (abcdefg) where the a/d positions are 
hydrophobic and e/g positions are charged ionic 
amino acids.
-De novo coiled coil design is well developed to 
control both oligomeric state, parallel/antiparallel 
orientation and specificity of interactions. 
Figure 4. Coiled coil helical wheel (top) and cartoon model 
(bottom) .
Figure 3. Design of a soluble RTK protein mimic comprised of the EGFR kinase domain.
Figure 5. Heterodimeric parallel coiled coil peptide design.3
-Insertion of genes encoding P1 or P2 into the 
pET28 plasmid with the gene encoding the EGFR 
KD would allow protein expression of a soluble 
fusion protein mimicking the RTK protein.
-Preliminary expression performed overnight at 30 °C showed a strong band by 
SDS-PAGE corresponding well with the molecular weight of P1-EGFR (44.7 kDa 
expected).
-Purification by nickel affinity yielded a soluble peak, but had a very low yield.
-Denatured nickel affinity chromatography produced better yields of soluble pure 
protein.
Figure 8. Expression and purification results for P1-EGFR. Left) Preliminary protein expression studies of P1-EGFR KD 
(expected molecular weight 44.7 kDa). Right) P1-EGFR purified by denatured nickel (Ni) affinity chromatography produced 


















































-Size exclusion chromatography of 
refolded P1-EGFR showed large 
molecular weight aggregation.
-E. coli expression is known to yield 
misfolded and inactive protein.
-Expression of P1-EGFR in insect cells 
has produced soluble, active protein that 
shows self dimerization of P1.
